AVANOS MEDICAL INC (AVNS) Fundamental Analysis & Valuation

NYSE:AVNS • US05350V1061

13.29 USD
-0.5 (-3.63%)
At close: Mar 6, 2026
13.29 USD
0 (0%)
After Hours: 3/6/2026, 8:04:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This AVNS fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

4

Taking everything into account, AVNS scores 4 out of 10 in our fundamental rating. AVNS was compared to 184 industry peers in the Health Care Equipment & Supplies industry. AVNS has an average financial health and profitability rating. AVNS is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

4

1. AVNS Profitability Analysis

1.1 Basic Checks

  • In the past year AVNS was profitable.
  • AVNS had a positive operating cash flow in the past year.
  • In multiple years AVNS reported negative net income over the last 5 years.
  • In the past 5 years AVNS always reported a positive cash flow from operatings.
AVNS Yearly Net Income VS EBIT VS OCF VS FCFAVNS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M -200M -300M

1.2 Ratios

  • With a decent Return On Assets value of -6.79%, AVNS is doing good in the industry, outperforming 65.76% of the companies in the same industry.
  • Looking at the Return On Equity, with a value of -9.37%, AVNS is in the better half of the industry, outperforming 68.48% of the companies in the same industry.
  • Looking at the Return On Invested Capital, with a value of 1.47%, AVNS is in the better half of the industry, outperforming 67.93% of the companies in the same industry.
  • AVNS had an Average Return On Invested Capital over the past 3 years of 1.82%. This is significantly below the industry average of 9.15%.
Industry RankSector Rank
ROA -6.79%
ROE -9.37%
ROIC 1.47%
ROA(3y)-14.8%
ROA(5y)-8.25%
ROE(3y)-20.56%
ROE(5y)-11.47%
ROIC(3y)1.82%
ROIC(5y)2.02%
AVNS Yearly ROA, ROE, ROICAVNS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -10 -20 -30 -40

1.3 Margins

  • AVNS has a Operating Margin of 2.41%. This is in the better half of the industry: AVNS outperforms 67.93% of its industry peers.
  • In the last couple of years the Operating Margin of AVNS has declined.
  • AVNS has a Gross Margin (50.47%) which is in line with its industry peers.
  • In the last couple of years the Gross Margin of AVNS has remained more or less at the same level.
Industry RankSector Rank
OM 2.41%
PM (TTM) N/A
GM 50.47%
OM growth 3Y-36.17%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.75%
GM growth 5Y-0.68%
AVNS Yearly Profit, Operating, Gross MarginsAVNS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40 -40

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. AVNS Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), AVNS is destroying value.
  • AVNS has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for AVNS has been reduced compared to 5 years ago.
  • The debt/assets ratio for AVNS has been reduced compared to a year ago.
AVNS Yearly Shares OutstandingAVNS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M
AVNS Yearly Total Debt VS Total AssetsAVNS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B

2.2 Solvency

  • AVNS has an Altman-Z score of 1.16. This is a bad value and indicates that AVNS is not financially healthy and even has some risk of bankruptcy.
  • AVNS's Altman-Z score of 1.16 is in line compared to the rest of the industry. AVNS outperforms 51.63% of its industry peers.
  • AVNS has a debt to FCF ratio of 2.33. This is a good value and a sign of high solvency as AVNS would need 2.33 years to pay back of all of its debts.
  • AVNS has a better Debt to FCF ratio (2.33) than 85.33% of its industry peers.
  • AVNS has a Debt/Equity ratio of 0.12. This is a healthy value indicating a solid balance between debt and equity.
  • AVNS has a Debt to Equity ratio of 0.12. This is in the better half of the industry: AVNS outperforms 64.13% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.12
Debt/FCF 2.33
Altman-Z 1.16
ROIC/WACC0.15
WACC9.73%
AVNS Yearly LT Debt VS Equity VS FCFAVNS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M 1B

2.3 Liquidity

  • AVNS has a Current Ratio of 2.15. This indicates that AVNS is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 2.15, AVNS is in line with its industry, outperforming 40.76% of the companies in the same industry.
  • A Quick Ratio of 1.26 indicates that AVNS should not have too much problems paying its short term obligations.
  • AVNS has a worse Quick ratio (1.26) than 66.85% of its industry peers.
Industry RankSector Rank
Current Ratio 2.15
Quick Ratio 1.26
AVNS Yearly Current Assets VS Current LiabilitesAVNS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. AVNS Growth Analysis

3.1 Past

  • The earnings per share for AVNS have decreased strongly by -25.40% in the last year.
  • AVNS shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 3.80% yearly.
  • The Revenue has been growing slightly by 1.95% in the past year.
  • The Revenue has been decreasing by -0.38% on average over the past years.
EPS 1Y (TTM)-25.4%
EPS 3Y-17.1%
EPS 5Y3.8%
EPS Q2Q%-30.95%
Revenue 1Y (TTM)1.95%
Revenue growth 3Y-5.08%
Revenue growth 5Y-0.38%
Sales Q2Q%0.72%

3.2 Future

  • Based on estimates for the next years, AVNS will show a quite strong growth in Earnings Per Share. The EPS will grow by 16.51% on average per year.
  • Based on estimates for the next years, AVNS will show a small growth in Revenue. The Revenue will grow by 3.19% on average per year.
EPS Next Y8.62%
EPS Next 2Y16.51%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year2.16%
Revenue Next 2Y3.19%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
AVNS Yearly Revenue VS EstimatesAVNS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 500M 1B 1.5B
AVNS Yearly EPS VS EstimatesAVNS Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0.5 1 1.5 2

More info and screens

Find the best growth stocksShow best growing peers

6

4. AVNS Valuation Analysis

4.1 Price/Earnings Ratio

  • AVNS is valuated correctly with a Price/Earnings ratio of 14.14.
  • Compared to the rest of the industry, the Price/Earnings ratio of AVNS indicates a rather cheap valuation: AVNS is cheaper than 87.50% of the companies listed in the same industry.
  • AVNS's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 26.29.
  • A Price/Forward Earnings ratio of 13.02 indicates a correct valuation of AVNS.
  • AVNS's Price/Forward Earnings ratio is rather cheap when compared to the industry. AVNS is cheaper than 89.67% of the companies in the same industry.
  • AVNS's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 24.60.
Industry RankSector Rank
PE 14.14
Fwd PE 13.02
AVNS Price Earnings VS Forward Price EarningsAVNS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, AVNS is valued cheaply inside the industry as 89.13% of the companies are valued more expensively.
  • 96.20% of the companies in the same industry are more expensive than AVNS, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 14.34
EV/EBITDA 11.27
AVNS Per share dataAVNS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15

4.3 Compensation for Growth

  • The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
  • A more expensive valuation may be justified as AVNS's earnings are expected to grow with 16.51% in the coming years.
PEG (NY)1.64
PEG (5Y)3.72
EPS Next 2Y16.51%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. AVNS Dividend Analysis

5.1 Amount

  • AVNS does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

AVNS Fundamentals: All Metrics, Ratios and Statistics

AVANOS MEDICAL INC

NYSE:AVNS (3/6/2026, 8:04:00 PM)

After market: 13.29 0 (0%)

13.29

-0.5 (-3.63%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-24
Earnings (Next)05-04
Inst Owners97.21%
Inst Owner Change27.64%
Ins Owners2.94%
Ins Owner Change-0.8%
Market Cap617.99M
Revenue(TTM)701.20M
Net Income(TTM)-72.90M
Analysts43.33
Price TargetN/A
Short Float %6.62%
Short Ratio4.97
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)47.19%
Min EPS beat(2)14.64%
Max EPS beat(2)79.74%
EPS beat(4)4
Avg EPS beat(4)36.78%
Min EPS beat(4)11.11%
Max EPS beat(4)79.74%
EPS beat(8)5
Avg EPS beat(8)16.95%
EPS beat(12)7
Avg EPS beat(12)15.54%
EPS beat(16)10
Avg EPS beat(16)13.47%
Revenue beat(2)2
Avg Revenue beat(2)3.74%
Min Revenue beat(2)1.52%
Max Revenue beat(2)5.97%
Revenue beat(4)4
Avg Revenue beat(4)3.17%
Min Revenue beat(4)1.52%
Max Revenue beat(4)5.97%
Revenue beat(8)4
Avg Revenue beat(8)0.74%
Revenue beat(12)4
Avg Revenue beat(12)-0.83%
Revenue beat(16)4
Avg Revenue beat(16)-4.39%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-36.96%
EPS NQ rev (3m)-36.96%
EPS NY rev (1m)5.37%
EPS NY rev (3m)5.37%
Revenue NQ rev (1m)-0.29%
Revenue NQ rev (3m)-0.29%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE 14.14
Fwd PE 13.02
P/S 0.88
P/FCF 14.34
P/OCF 8.27
P/B 0.79
P/tB 2.33
EV/EBITDA 11.27
EPS(TTM)0.94
EY7.07%
EPS(NY)1.02
Fwd EY7.68%
FCF(TTM)0.93
FCFY6.97%
OCF(TTM)1.61
OCFY12.09%
SpS15.08
BVpS16.74
TBVpS5.71
PEG (NY)1.64
PEG (5Y)3.72
Graham Number18.81
Profitability
Industry RankSector Rank
ROA -6.79%
ROE -9.37%
ROCE 1.86%
ROIC 1.47%
ROICexc 1.63%
ROICexgc 4.36%
OM 2.41%
PM (TTM) N/A
GM 50.47%
FCFM 6.15%
ROA(3y)-14.8%
ROA(5y)-8.25%
ROE(3y)-20.56%
ROE(5y)-11.47%
ROIC(3y)1.82%
ROIC(5y)2.02%
ROICexc(3y)2.02%
ROICexc(5y)2.23%
ROICexgc(3y)5.81%
ROICexgc(5y)7.12%
ROCE(3y)2.3%
ROCE(5y)2.56%
ROICexgc growth 3Y-33.59%
ROICexgc growth 5YN/A
ROICexc growth 3Y-26.31%
ROICexc growth 5YN/A
OM growth 3Y-36.17%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.75%
GM growth 5Y-0.68%
F-Score6
Asset Turnover0.65
Health
Industry RankSector Rank
Debt/Equity 0.12
Debt/FCF 2.33
Debt/EBITDA 1.62
Cap/Depr 81.23%
Cap/Sales 4.51%
Interest Coverage 2.6
Cash Conversion 133.87%
Profit Quality N/A
Current Ratio 2.15
Quick Ratio 1.26
Altman-Z 1.16
F-Score6
WACC9.73%
ROIC/WACC0.15
Cap/Depr(3y)52.99%
Cap/Depr(5y)50.85%
Cap/Sales(3y)3.25%
Cap/Sales(5y)2.98%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-25.4%
EPS 3Y-17.1%
EPS 5Y3.8%
EPS Q2Q%-30.95%
EPS Next Y8.62%
EPS Next 2Y16.51%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)1.95%
Revenue growth 3Y-5.08%
Revenue growth 5Y-0.38%
Sales Q2Q%0.72%
Revenue Next Year2.16%
Revenue Next 2Y3.19%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-62.19%
EBIT growth 3Y-39.42%
EBIT growth 5YN/A
EBIT Next Year165.31%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-48.01%
FCF growth 3Y-15.57%
FCF growth 5YN/A
OCF growth 1Y-25.82%
OCF growth 3Y-6.33%
OCF growth 5YN/A

AVANOS MEDICAL INC / AVNS FAQ

Can you provide the ChartMill fundamental rating for AVANOS MEDICAL INC?

ChartMill assigns a fundamental rating of 4 / 10 to AVNS.


What is the valuation status for AVNS stock?

ChartMill assigns a valuation rating of 6 / 10 to AVANOS MEDICAL INC (AVNS). This can be considered as Fairly Valued.


Can you provide the profitability details for AVANOS MEDICAL INC?

AVANOS MEDICAL INC (AVNS) has a profitability rating of 4 / 10.


Can you provide the expected EPS growth for AVNS stock?

The Earnings per Share (EPS) of AVANOS MEDICAL INC (AVNS) is expected to grow by 8.62% in the next year.